Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
MBRX
$2.58
$
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Next Earnings
2026-02-25
Beta
1.668
Average Volume
Market Cap
Last Dividend
CIK
0001659617
ISIN
US60855D4088
CUSIP
60855D309
CEO
Walter V. Klemp
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
17
IPO Date
2016-06-02
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds | HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,122,652 shares of common stock of the Company at an exercise price of $3.90 per share. The issuance or resale of the shares of common stock issuable upon exercise of the outstanding warrants has been registered pursuant to effective registration statements. The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $8.3 million, before deducting financial advisory fees. Roth Capital Partners is acting as the Company's financial advisor for this transaction. In consideration for the immediate exercise of the warrants for cash, the Company will issue new unregistered warrants to purchase shares of common stock. The new warrants will be exercisable for an aggregate of up to 6,367,956 shares of common stock, at an exercise price equal to the lesser of $3.90 per share or the lowest volume weighted average price of the Company's common stock on any trading day during the next five trading days, will be exercisable upon shareholder approval and for a term of five years from the date of shareholder approval. The transaction is expected to close on or about February 20, 2026, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. The new warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the “1933 Act”) and, along with the shares of common stock issuable upon their exercise, have not been registered under the 1933 Act, and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Moleculin Biotech, Inc. | GlobeNewsWire | 2026-02-19 08:39:00 |
| Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) | Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failures First 45 subjects treated on track for Q1 2026 milestone with unblinding thereafter; treated 35 subjects to date with another 11 identified Continued absence of cardiotoxicity and high efficacy expected to position Annamycin as a “significant advancement” in AML treatment HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it is approaching the first unblinding of data in its pivotal Phase 2B/3 “MIRACLE” study of Annamycin in combination with cytarabine for the treatment of adult patients with acute myeloid leukemia (AML) who are refractory to or relapsed (R/R) after induction therapy (R/R AML), having treated 35 subjects to date with another 11 in screening or identified. Additional subjects continue to be identified by site investigators. | GlobeNewsWire | 2026-02-18 08:20:00 |
| Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin | HOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of allowance for Patent Application No. 2021-577862 titled, “METHOD OF RECONSTITUTING LIPOSOMAL ANNAMYCIN.” A patent from the application is expected to be issued in the coming months. | GlobeNewsWire | 2026-02-17 08:35:00 |
| Moleculin Biotech Highlights Phase 3 Annamycin AML Catalysts, Eyes Partnering Within 12 Months | Moleculin Biotech (NASDAQ: MBRX) CEO and Chairman Walter Klemp outlined the company's near-term priorities and upcoming clinical catalysts during a corporate presentation, emphasizing progress in its Phase 3 program for Annamycin, a next-generation anthracycline being developed primarily for acute myeloid leukemia (AML). Company focus and management background Klemp described Moleculin as a "Phase 3 clinical stage | Defense World | 2026-02-16 01:02:57 |
| Moleculin Launches CEO Corner Platform to Share Strategic Insights | CEO Corner segments intended to provide added perspective to press releases, clinical trial developments and pipeline progress Provides interested parties with the ability to connect with the Company by submitting questions and topics for future videos Access the Moleculin CEO Corner here HOUSTON, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the launch of its CEO Corner, a new platform featuring Walter Klemp, Chief Executive Officer. The CEO Corner is designed to provide investors and stakeholders with enhanced insight into the Company's corporate developments, clinical progress and strategic initiatives. | GlobeNewsWire | 2026-02-13 08:32:00 |
| Moleculin Biotech (NASDAQ:MBRX) Stock Crosses Below Fifty Day Moving Average – Time to Sell? | Moleculin Biotech, Inc. (NASDAQ: MBRX - Get Free Report) shares passed below its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $4.58 and traded as low as $3.85. Moleculin Biotech shares last traded at $4.31, with a volume of 158,257 shares changing hands. Analyst Ratings Changes | Defense World | 2026-02-07 04:38:47 |
| Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial | – Live video webcast on Wednesday, February 11 th at 1:20 PM EST | GlobeNewsWire | 2026-02-05 09:15:00 |
| Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects | – Annamycin consistently demonstrates no evidence of cardiotoxicity across five clinical trials – This next-generation anthracycline demonstrates safety and promising early activity in treating multiple oncology indications HOUSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), announced it has received a new independent assessment for the absence of cardiotoxicity in subjects treated with Annamycin, bringing the total number of Annamycin treated subjects reviewed by its independent expert to 90. Data from the most recently completed clinical trials' subjects were made available to an expert in chemotherapy who is affiliated with a leading cancer research institute in assessing cardiotoxicity. | GlobeNewsWire | 2026-01-13 08:55:00 |
| Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs | – First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries – Investigator-Initiated (IIT) funded pancreatic and brain cancer trials HOUSTON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today provided a business outlook and outlined expected upcoming milestones for its next generation non-cardiotoxic anthracycline Annamycin (also known by its generic name “naxtarubicin”) and its STAT3 inhibitor WP1066. Annamycin “Annamycin is set for a number of milestones in 2026 including two data readouts in its pivotal Phase 2B/3 MIRACLE trial treating second line (2L) acute myeloid leukemia (AML) plus embarking in its first clinical trial for the treatment of pancreatic cancer,” commented Walter Klemp, Chairman and CEO of Moleculin. | GlobeNewsWire | 2026-01-12 08:36:00 |
| Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors | Emory University physician-sponsored clinical trial conducted at the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta Results demonstrated WP1066 induces anti-tumor immune responses and were recently published in the Journal of Clinical Investigation Insight | GlobeNewsWire | 2025-12-17 08:31:00 |
| Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds | HOUSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 727,969 shares of common stock of the Company originally issued in February 2025 at an exercise price of $6.63 per share and 316,360 shares of common stock of the Company originally issued in August 2025 at an exercise price of $6.3219 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to effective registration statements on Form S-1 (File No. | GlobeNewsWire | 2025-12-10 08:30:00 |
| Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026 | Continues to drive enrollment with increase to 78% now consented Blinded response activity tracking within expected range | GlobeNewsWire | 2025-12-09 08:07:00 |
| Moleculin Announces New Annamycin Collaboration in Brain Tumors | Investigator-Initiated Preclinical studies at CIC biomaGUNE aimed at combatting Glioblastoma Multiforme Research will evaluate effects of intra-arterial delivery of Annamycin HOUSTON, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viral infections, today announced it has entered into a research and material transfer agreement with CIC biomaGUNE, a non-profit research organization created to promote scientific research and technological innovation at the highest levels in the Basque Country, Spain, for investigator-initiated preclinical research evaluating Annamycin for the treatment of glioblastoma multiforme (GBM), a form of brain cancer. Under the terms of the agreement Moleculin will supply Annamycin and Jesús Ruiz-Cabello, Principal Investigator at CIC biomaGUNE will conduct the planned preclinical research. | GlobeNewsWire | 2025-12-08 08:21:00 |
| Moleculin to Participate in the Virtual Investor Closing Bell Series | Live video webcast with Walter Klemp, Chairman and Chief Executive Officer, on Tuesday, December 2 nd at 4:00 PM ET | GlobeNewsWire | 2025-11-26 09:15:00 |
| Moleculin Announces Reverse Stock Split | HOUSTON, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-25 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on December 1, 2025, and the Company's common stock will open for trading on The Nasdaq Capital Market on December 1, 2025 on a post-split basis, under the existing ticker symbol “MBRX” but with a new CUSIP number 60855D 408. | GlobeNewsWire | 2025-11-26 09:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2026-02-20 | 2026-02-20 | View Filing |
| 8-K | 2026-02-18 | 2026-02-18 | View Filing |
| 8-K | 2026-02-18 | 2026-02-18 | View Filing |
| 8-K | 2026-02-17 | 2026-02-17 | View Filing |
| 8-K | 2026-02-05 | 2026-02-05 | View Filing |
| 8-K | 2026-01-20 | 2026-01-20 | View Filing |
| 8-K | 2026-01-13 | 2026-01-13 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2026-01-07 | 2026-01-07 | View Filing |
| EFFECT | 2026-01-06 | 2026-01-07 | View Filing |
| DEF 14A | 2026-01-02 | 2026-01-02 | View Filing |
| S-3 | 2025-12-23 | 2025-12-23 | View Filing |
| 424B5 | 2025-12-23 | 2025-12-23 | View Filing |
| PRER14A | 2025-12-22 | 2025-12-22 | View Filing |
| 8-K | 2025-12-22 | 2025-12-22 | View Filing |
| PRE 14A | 2025-12-19 | 2025-12-19 | View Filing |
| 8-K | 2025-12-17 | 2025-12-17 | View Filing |
| 8-K | 2025-12-16 | 2025-12-16 | View Filing |
| 8-K | 2025-12-10 | 2025-12-10 | View Filing |
| 8-K | 2025-12-09 | 2025-12-09 | View Filing |
| 8-K | 2025-12-08 | 2025-12-08 | View Filing |
| 8-K | 2025-11-28 | 2025-11-28 | View Filing |
| 8-K | 2025-11-24 | 2025-11-24 | View Filing |
| 8-K | 2025-11-21 | 2025-11-21 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 4 | 2025-11-14 | 2025-11-14 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 4 | 2025-11-06 | 2025-11-06 | View Filing |
| 4 | 2025-11-06 | 2025-11-06 | View Filing |
| 4 | 2025-11-06 | 2025-11-06 | View Filing |
| 8-K | 2025-10-30 | 2025-10-30 | View Filing |
| 8-K | 2025-10-29 | 2025-10-29 | View Filing |
| 8-K | 2025-10-23 | 2025-10-23 | View Filing |
| 8-K | 2025-10-16 | 2025-10-16 | View Filing |
| 424B3 | 2025-10-03 | 2025-10-03 | View Filing |
| EFFECT | 2025-10-01 | 2025-10-01 | View Filing |
| 8-K | 2025-09-25 | 2025-09-25 | View Filing |
| S-3 | 2025-09-19 | 2025-09-19 | View Filing |
| DEF 14A | 2025-09-15 | 2025-09-15 | View Filing |
| S-8 | 2025-09-10 | 2025-09-10 | View Filing |
| 8-K | 2025-09-09 | 2025-09-09 | View Filing |
| 8-K | 2025-09-08 | 2025-09-08 | View Filing |
| 8-K | 2025-09-08 | 2025-09-08 | View Filing |
| PRE 14A | 2025-09-05 | 2025-09-05 | View Filing |
| 8-K | 2025-08-29 | 2025-08-28 | View Filing |
| 8-K | 2025-08-27 | 2025-08-27 | View Filing |
| 8-K | 2025-08-18 | 2025-08-18 | View Filing |
| 8-K | 2025-08-18 | 2025-08-18 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-08-13 | 2025-08-13 | View Filing |
| 10-Q | 2025-08-12 | 2025-08-12 | View Filing |
| 8-K | 2025-08-06 | 2025-08-06 | View Filing |
| 8-K | 2025-08-01 | 2025-08-01 | View Filing |
| 8-K | 2025-07-30 | 2025-07-30 | View Filing |
| 8-K | 2025-07-17 | 2025-07-17 | View Filing |
| 8-K | 2025-07-11 | 2025-07-11 | View Filing |
| 424B5 | 2025-07-11 | 2025-07-11 | View Filing |
| 8-K | 2025-07-09 | 2025-07-09 | View Filing |
| DEFA14A | 2025-07-08 | 2025-07-08 | View Filing |
| DEF 14A | 2025-07-08 | 2025-07-08 | View Filing |
| PRE 14A | 2025-06-27 | 2025-06-27 | View Filing |
| 8-K | 2025-06-27 | 2025-06-27 | View Filing |
| 8-K | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-23 | 2025-06-23 | View Filing |
| 424B4 | 2025-06-23 | 2025-06-23 | View Filing |
| EFFECT | 2025-06-23 | 2025-06-23 | View Filing |
| 4 | 2025-06-18 | 2025-06-18 | View Filing |
| 4 | 2025-06-18 | 2025-06-18 | View Filing |
| 8-K | 2025-06-18 | 2025-06-18 | View Filing |
| S-1/A | 2025-06-16 | 2025-06-16 | View Filing |
| S-1/A | 2025-06-11 | 2025-06-11 | View Filing |
| S-1/A | 2025-06-06 | 2025-06-06 | View Filing |
| 8-K | 2025-06-05 | 2025-06-05 | View Filing |
| 8-K | 2025-06-04 | 2025-06-04 | View Filing |
| S-1 | 2025-06-02 | 2025-06-02 | View Filing |
| PRE 14A | 2025-05-23 | 2025-05-23 | View Filing |
| 8-K | 2025-05-23 | 2025-05-23 | View Filing |
| SC 13G/A | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-12 | 2025-05-12 | View Filing |
| 8-K | 2025-05-09 | 2025-05-09 | View Filing |
| 8-K | 2025-05-07 | 2025-05-07 | View Filing |
| 8-K | 2025-05-06 | 2025-05-06 | View Filing |
| 8-K | 2025-05-05 | 2025-05-05 | View Filing |
| 10-K/A | 2025-04-30 | 2025-04-30 | View Filing |
| 8-K | 2025-04-29 | 2025-04-29 | View Filing |
| 8-K | 2025-04-25 | 2025-04-25 | View Filing |
| 8-K | 2025-04-21 | 2025-04-21 | View Filing |
| 10-K/A | 2025-04-18 | 2025-04-18 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Neural Forcast | 17.64% | 1.18 | 20 | 0.65 | 0.49 | 18 |
| Swarm Intelligence Strategy | 15.40% | 1.08 | 39 | 0.33 | 0.11 | 15.77 |
| Pivot Points Strategy | 15.01% | 1.44 | 13 | 0.5 | 0.36 | 15.38 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | x | x | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxx | xxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | x | x | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |